literature

HIV mutation literature information.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

PMID: 22132100 2011 PloS one

Method: The only additions to this list since that time are K101H, E138A, and M230L, all etravirine-associated changes and K101P associated with resistance to NVP, EFV and etravirine.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

PMID: 22024527 2011 Antiviral therapy

Abstract: The RVP resistance-associated mutations (RAMs) detected were K101P (1.8%), Y181I (2.7%) and Y181V (3.6%).

Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.

PMID: 21592625 2011 Enfermedades infecciosas y microbiologia clinica

Abstract: ETR-RAMs were defined as V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, and M230L, and were analyzed according to the weighted mutation score to predict susceptibility (Vingerhoets 2008).

Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

PMID: 21464253 2011 Antimicrobial agents and chemotherapy

Abstract: N348I or T369I was associated with reduced etravirine susceptibility when present with K101P or K103R/V179D.

N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.

PMID: 20010074 2010 AIDS (London, England)

Introduction: Since the presence of three or more NNRTI mutations V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V and G190A/S results in no response to etravirine treatment, the presence of two of these NNRTI mutations and N348I at baseline may also reduce etravirine efficacy in vivo.

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

PMID: 19933797 2010 Antimicrobial agents and chemotherapy

Abstract: The HIV-1 site-directed mutant with Y181C was sensitive to TMC278, whereas that with K101P or Y181I/V was resistant.

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.

PMID: 20188624 2010 Journal of clinical virology

Abstract: Higher proportion of K101E, K101P, Y181C, G190S, and M230L were found in patients with a score of > or =2.5 (p<0.05, all).

[Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy].

PMID: 20450778 2010 Zhonghua yi xue za zhi

Abstract: K103N, G190A, Y181C, K101P, M184V, D67N, K70R, T215Y and K219 were most common mutations.

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 20462946 2010 The Journal of antimicrobial chemotherapy

Abstract: Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data.

Abstract: RESULTS: Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P < 0.001), K101P (3.3% versus 0.4%, P < 0.001) and M230L (2.8% versus 1.3%, P = 0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P < 0.001).

Abstract: Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (

Genetic characterization of HIV type 1 among patients with suspected immune reconstitution inflammatory syndrome after initiation of antiretroviral therapy in Kenya.

PMID: 20624074 2010 AIDS research and human retroviruses

Abstract: These included nucleoside reverse transcriptase inhibitor (RTI) mutations: M41L, K65R, D67N, K70R, M184V, and K219Q, and nonnucleoside RTI mutations: K101P, L100I, K103N, and Y181C.

Browser Board

Co-occurred Entities

Filtrator